Aspire Biopharma (ASBP) & The Competition Head to Head Comparison

Aspire Biopharma (NASDAQ:ASBP) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its competitors? We will compare Aspire Biopharma to similar companies based on the strength of its risk, profitability, valuation, dividends, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Aspire Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-1,052.55%
Aspire Biopharma Competitors	-1,425.99%	-589.65%	-28.81%

Volatility and Risk

Aspire Biopharma has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Aspire Biopharma’s competitors have a beta of 0.97, suggesting that their average stock price is 3% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Aspire Biopharma and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1	0	0	0	1.00
Aspire Biopharma Competitors	5856	12211	37670	1170	2.60

As a group, “MED – BIOMED/GENE” companies have a potential upside of 50.89%. Given Aspire Biopharma’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Aspire Biopharma has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 51.3% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 25.8% of Aspire Biopharma shares are held by company insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Aspire Biopharma and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aspire Biopharma	N/A	-$12.54 million	-0.20
Aspire Biopharma Competitors	$959.04 million	-$45.27 million	12.93

Aspire Biopharma’s competitors have higher revenue, but lower earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Aspire Biopharma competitors beat Aspire Biopharma on 9 of the 13 factors compared.

About Aspire Biopharma

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.